 Douglas Seals
Concepts (779)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aging | 201 | 2026 | 1946 | 20.450 |
Why?
| | Endothelium, Vascular | 88 | 2026 | 962 | 15.190 |
Why?
| | Vascular Stiffness | 48 | 2026 | 463 | 9.950 |
Why?
| | Oxidative Stress | 70 | 2026 | 1370 | 8.490 |
Why?
| | Vasodilation | 63 | 2025 | 515 | 7.980 |
Why?
| | Exercise | 103 | 2025 | 2151 | 7.970 |
Why?
| | Arteries | 33 | 2024 | 261 | 6.440 |
Why?
| | Sympathetic Nervous System | 69 | 2026 | 178 | 6.340 |
Why?
| | Brachial Artery | 41 | 2026 | 209 | 6.290 |
Why?
| | Blood Pressure | 106 | 2026 | 1755 | 6.060 |
Why?
| | Biomedical Research | 12 | 2024 | 699 | 4.830 |
Why?
| | Writing | 8 | 2024 | 99 | 4.560 |
Why?
| | Carotid Arteries | 29 | 2025 | 202 | 4.250 |
Why?
| | Aorta | 21 | 2026 | 433 | 4.080 |
Why?
| | Vascular Diseases | 15 | 2023 | 246 | 3.630 |
Why?
| | Antioxidants | 25 | 2026 | 594 | 3.470 |
Why?
| | Cardiovascular Diseases | 31 | 2026 | 2113 | 3.320 |
Why?
| | Nitric Oxide | 34 | 2025 | 899 | 3.320 |
Why?
| | Regional Blood Flow | 36 | 2020 | 504 | 3.180 |
Why?
| | Physiology | 5 | 2024 | 13 | 3.030 |
Why?
| | Physical Endurance | 48 | 2016 | 278 | 2.990 |
Why?
| | Publishing | 5 | 2023 | 111 | 2.970 |
Why?
| | Sodium Nitrite | 8 | 2021 | 39 | 2.940 |
Why?
| | Heart Rate | 84 | 2023 | 844 | 2.900 |
Why?
| | Postmenopause | 28 | 2026 | 377 | 2.890 |
Why?
| | Endothelial Cells | 23 | 2026 | 846 | 2.820 |
Why?
| | Resistance Training | 5 | 2023 | 170 | 2.640 |
Why?
| | Aged | 182 | 2026 | 25322 | 2.580 |
Why?
| | Hypertension | 24 | 2025 | 1260 | 2.540 |
Why?
| | Mitochondria | 12 | 2026 | 988 | 2.510 |
Why?
| | Dietary Supplements | 22 | 2026 | 587 | 2.450 |
Why?
| | Pulse Wave Analysis | 25 | 2026 | 245 | 2.330 |
Why?
| | Caloric Restriction | 10 | 2021 | 125 | 2.320 |
Why?
| | Blood Vessels | 6 | 2020 | 175 | 2.320 |
Why?
| | Middle Aged | 205 | 2026 | 35342 | 2.260 |
Why?
| | Exercise Tolerance | 10 | 2026 | 285 | 2.200 |
Why?
| | Physical Exertion | 34 | 2014 | 209 | 2.200 |
Why?
| | Cellular Senescence | 12 | 2026 | 227 | 2.180 |
Why?
| | Diet, Sodium-Restricted | 8 | 2020 | 38 | 2.150 |
Why?
| | Male | 268 | 2026 | 71500 | 2.050 |
Why?
| | Humans | 359 | 2026 | 143560 | 2.040 |
Why?
| | Nitric Oxide Synthase Type III | 13 | 2020 | 201 | 2.010 |
Why?
| | Inflammation | 24 | 2024 | 2881 | 1.990 |
Why?
| | Muscles | 32 | 2023 | 331 | 1.960 |
Why?
| | Ascorbic Acid | 17 | 2025 | 180 | 1.960 |
Why?
| | Physical Fitness | 20 | 2013 | 207 | 1.950 |
Why?
| | Baroreflex | 16 | 2016 | 57 | 1.920 |
Why?
| | Physical Conditioning, Animal | 10 | 2021 | 247 | 1.880 |
Why?
| | Methylamines | 6 | 2022 | 40 | 1.860 |
Why?
| | Oxygen Consumption | 47 | 2023 | 718 | 1.860 |
Why?
| | Cardiovascular Physiological Phenomena | 13 | 2019 | 46 | 1.840 |
Why?
| | NF-kappa B | 9 | 2015 | 685 | 1.820 |
Why?
| | Peer Review | 4 | 2023 | 46 | 1.790 |
Why?
| | Superoxides | 16 | 2022 | 208 | 1.790 |
Why?
| | Vasodilator Agents | 12 | 2024 | 330 | 1.760 |
Why?
| | Acetylcholine | 12 | 2023 | 204 | 1.660 |
Why?
| | Mice | 60 | 2026 | 18378 | 1.600 |
Why?
| | Animals | 91 | 2026 | 38010 | 1.580 |
Why?
| | Norepinephrine | 29 | 2011 | 192 | 1.560 |
Why?
| | Diet, Western | 3 | 2022 | 82 | 1.500 |
Why?
| | Adult | 204 | 2026 | 40013 | 1.500 |
Why?
| | Female | 186 | 2026 | 77251 | 1.480 |
Why?
| | Heart | 16 | 2018 | 632 | 1.460 |
Why?
| | Mice, Inbred C57BL | 33 | 2026 | 6043 | 1.430 |
Why?
| | Healthy Aging | 4 | 2024 | 37 | 1.410 |
Why?
| | Doxorubicin | 6 | 2026 | 381 | 1.410 |
Why?
| | Adipose Tissue | 19 | 2018 | 654 | 1.410 |
Why?
| | Vascular Resistance | 20 | 2012 | 365 | 1.380 |
Why?
| | Motor Activity | 8 | 2024 | 721 | 1.330 |
Why?
| | Salicylates | 5 | 2015 | 29 | 1.310 |
Why?
| | Respiratory Muscles | 5 | 2023 | 36 | 1.300 |
Why?
| | Forearm | 18 | 2023 | 139 | 1.290 |
Why?
| | NADPH Oxidases | 13 | 2020 | 131 | 1.260 |
Why?
| | Muscle, Skeletal | 25 | 2026 | 1787 | 1.210 |
Why?
| | Reactive Oxygen Species | 15 | 2026 | 642 | 1.210 |
Why?
| | Autonomic Nervous System | 11 | 2008 | 79 | 1.210 |
Why?
| | Research Personnel | 4 | 2023 | 178 | 1.200 |
Why?
| | Age Factors | 29 | 2025 | 3328 | 1.160 |
Why?
| | Double-Blind Method | 17 | 2025 | 2017 | 1.150 |
Why?
| | Estrogens | 8 | 2023 | 372 | 1.140 |
Why?
| | Tyrosine | 14 | 2020 | 229 | 1.110 |
Why?
| | Healthy Lifestyle | 2 | 2018 | 35 | 1.100 |
Why?
| | Vasoconstriction | 7 | 2017 | 216 | 1.090 |
Why?
| | Aorta, Thoracic | 4 | 2014 | 285 | 1.050 |
Why?
| | Femoral Artery | 11 | 2013 | 188 | 1.040 |
Why?
| | NAD | 5 | 2023 | 78 | 1.030 |
Why?
| | Smoking Water Pipes | 2 | 2023 | 9 | 1.010 |
Why?
| | Geriatrics | 4 | 2015 | 98 | 1.000 |
Why?
| | Water Pipe Smoking | 2 | 2023 | 9 | 1.000 |
Why?
| | Estrogen Replacement Therapy | 12 | 2013 | 143 | 1.000 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 4 | 2015 | 352 | 0.980 |
Why?
| | Inflammation Mediators | 6 | 2025 | 510 | 0.980 |
Why?
| | Receptors, Adrenergic, beta | 6 | 2008 | 66 | 0.950 |
Why?
| | Longevity | 4 | 2015 | 175 | 0.900 |
Why?
| | Metabolomics | 4 | 2021 | 715 | 0.900 |
Why?
| | Cross-Over Studies | 11 | 2026 | 583 | 0.900 |
Why?
| | Cyclic N-Oxides | 8 | 2020 | 34 | 0.880 |
Why?
| | Interleukin-1 | 5 | 2022 | 970 | 0.880 |
Why?
| | Bottle-Nosed Dolphin | 1 | 2024 | 3 | 0.870 |
Why?
| | Curcumin | 2 | 2017 | 28 | 0.870 |
Why?
| | Elasticity | 11 | 2017 | 193 | 0.870 |
Why?
| | Work-Life Balance | 1 | 2024 | 22 | 0.850 |
Why?
| | Drinking Water | 2 | 2022 | 96 | 0.850 |
Why?
| | Habits | 7 | 2017 | 51 | 0.840 |
Why?
| | Niacinamide | 4 | 2025 | 82 | 0.830 |
Why?
| | Trehalose | 4 | 2017 | 34 | 0.820 |
Why?
| | Career Choice | 2 | 2024 | 234 | 0.810 |
Why?
| | Cardiorespiratory Fitness | 3 | 2025 | 69 | 0.800 |
Why?
| | Financing, Organized | 1 | 2023 | 35 | 0.800 |
Why?
| | Body Composition | 30 | 2012 | 711 | 0.800 |
Why?
| | Gastrointestinal Microbiome | 3 | 2020 | 732 | 0.800 |
Why?
| | Physical Education and Training | 15 | 2024 | 73 | 0.800 |
Why?
| | Peer Review, Research | 1 | 2023 | 33 | 0.800 |
Why?
| | Body Temperature Regulation | 7 | 2007 | 104 | 0.790 |
Why?
| | Compliance | 15 | 2017 | 50 | 0.790 |
Why?
| | Research Support as Topic | 1 | 2023 | 81 | 0.790 |
Why?
| | Dementia | 2 | 2025 | 292 | 0.780 |
Why?
| | Fenofibrate | 2 | 2013 | 27 | 0.780 |
Why?
| | Human Umbilical Vein Endothelial Cells | 3 | 2021 | 108 | 0.770 |
Why?
| | Elastin | 6 | 2023 | 79 | 0.770 |
Why?
| | Goals | 1 | 2024 | 182 | 0.760 |
Why?
| | Vaping | 1 | 2023 | 66 | 0.760 |
Why?
| | Glycation End Products, Advanced | 4 | 2025 | 85 | 0.750 |
Why?
| | Lyases | 1 | 2022 | 15 | 0.750 |
Why?
| | Sodium, Dietary | 4 | 2013 | 38 | 0.750 |
Why?
| | Nicotinamide Mononucleotide | 3 | 2023 | 9 | 0.750 |
Why?
| | Renal Insufficiency, Chronic | 7 | 2025 | 637 | 0.740 |
Why?
| | Young Adult | 29 | 2025 | 13972 | 0.740 |
Why?
| | Hypolipidemic Agents | 2 | 2013 | 95 | 0.740 |
Why?
| | Muscle Strength | 6 | 2023 | 333 | 0.730 |
Why?
| | Transcriptome | 3 | 2023 | 1029 | 0.730 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2023 | 108 | 0.730 |
Why?
| | Rest | 13 | 2007 | 128 | 0.720 |
Why?
| | Research Design | 4 | 2022 | 1123 | 0.720 |
Why?
| | Speech | 1 | 2022 | 75 | 0.720 |
Why?
| | Stress, Physiological | 12 | 2017 | 453 | 0.710 |
Why?
| | Obesity | 14 | 2023 | 3041 | 0.710 |
Why?
| | Hemodynamics | 17 | 2023 | 1117 | 0.710 |
Why?
| | Aortitis | 2 | 2011 | 10 | 0.710 |
Why?
| | Vagus Nerve | 7 | 2005 | 91 | 0.700 |
Why?
| | Spirostans | 1 | 2021 | 4 | 0.700 |
Why?
| | Breathing Exercises | 1 | 2021 | 21 | 0.700 |
Why?
| | Inhalation | 1 | 2021 | 29 | 0.700 |
Why?
| | Spin Labels | 8 | 2020 | 54 | 0.690 |
Why?
| | Leg | 14 | 2007 | 240 | 0.690 |
Why?
| | Flavonoids | 3 | 2026 | 88 | 0.690 |
Why?
| | Models, Animal | 6 | 2024 | 392 | 0.690 |
Why?
| | Running | 16 | 2017 | 229 | 0.680 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2021 | 1226 | 0.670 |
Why?
| | Superoxide Dismutase | 9 | 2016 | 346 | 0.670 |
Why?
| | Reference Values | 26 | 2021 | 811 | 0.660 |
Why?
| | Autophagy | 3 | 2017 | 287 | 0.660 |
Why?
| | Ubiquinone | 2 | 2026 | 35 | 0.660 |
Why?
| | Isometric Contraction | 14 | 1996 | 184 | 0.660 |
Why?
| | Comprehension | 1 | 2022 | 183 | 0.650 |
Why?
| | Life Style | 14 | 2017 | 483 | 0.650 |
Why?
| | Biomarkers | 19 | 2025 | 4241 | 0.650 |
Why?
| | Frailty | 2 | 2024 | 180 | 0.650 |
Why?
| | Cardiac Output | 15 | 2004 | 179 | 0.640 |
Why?
| | Cytokines | 10 | 2019 | 2097 | 0.640 |
Why?
| | Fasting | 2 | 2020 | 284 | 0.640 |
Why?
| | Nitroglycerin | 3 | 2020 | 14 | 0.630 |
Why?
| | Exercise Therapy | 9 | 2025 | 459 | 0.630 |
Why?
| | Organophosphorus Compounds | 2 | 2026 | 82 | 0.620 |
Why?
| | Spermidine | 2 | 2024 | 18 | 0.600 |
Why?
| | Nitrites | 3 | 2014 | 88 | 0.600 |
Why?
| | Physical Conditioning, Human | 1 | 2019 | 40 | 0.600 |
Why?
| | Cardiovascular System | 10 | 2020 | 137 | 0.590 |
Why?
| | Isoproterenol | 4 | 2007 | 101 | 0.590 |
Why?
| | Overweight | 3 | 2009 | 598 | 0.580 |
Why?
| | Adrenergic beta-Agonists | 4 | 2007 | 97 | 0.580 |
Why?
| | Mentoring | 1 | 2021 | 150 | 0.580 |
Why?
| | Sirtuin 1 | 3 | 2016 | 35 | 0.580 |
Why?
| | Energy Metabolism | 9 | 2007 | 939 | 0.570 |
Why?
| | Adolescent | 46 | 2023 | 22481 | 0.570 |
Why?
| | Sex Characteristics | 13 | 2011 | 793 | 0.570 |
Why?
| | Lipids | 6 | 2018 | 704 | 0.560 |
Why?
| | Adaptation, Physiological | 8 | 2019 | 571 | 0.560 |
Why?
| | Flavonols | 4 | 2026 | 26 | 0.550 |
Why?
| | Lipoproteins, LDL | 10 | 2023 | 112 | 0.550 |
Why?
| | Health Status | 3 | 2019 | 824 | 0.550 |
Why?
| | Amino Acids | 2 | 2019 | 511 | 0.550 |
Why?
| | Body Constitution | 4 | 2005 | 54 | 0.540 |
Why?
| | Blood Volume | 8 | 1998 | 65 | 0.540 |
Why?
| | Sodium Chloride, Dietary | 3 | 2019 | 31 | 0.540 |
Why?
| | Tunica Intima | 7 | 2006 | 76 | 0.530 |
Why?
| | Muscle, Smooth, Vascular | 6 | 2017 | 450 | 0.530 |
Why?
| | Nitroprusside | 5 | 2011 | 72 | 0.520 |
Why?
| | Diet | 6 | 2024 | 1290 | 0.520 |
Why?
| | Epinephrine | 14 | 2007 | 148 | 0.510 |
Why?
| | Time Factors | 22 | 2026 | 7031 | 0.500 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2022 | 2177 | 0.500 |
Why?
| | Serine | 2 | 2015 | 149 | 0.500 |
Why?
| | Extracellular Matrix | 1 | 2021 | 558 | 0.500 |
Why?
| | Transcription Factor RelA | 4 | 2011 | 87 | 0.500 |
Why?
| | Basal Metabolism | 4 | 2004 | 64 | 0.500 |
Why?
| | Diet Therapy | 1 | 2016 | 37 | 0.500 |
Why?
| | Muscle Contraction | 13 | 2003 | 430 | 0.500 |
Why?
| | Glucose | 4 | 2019 | 1042 | 0.500 |
Why?
| | Primary Prevention | 1 | 2018 | 202 | 0.480 |
Why?
| | Cognition | 3 | 2025 | 1261 | 0.480 |
Why?
| | Estradiol | 3 | 2021 | 525 | 0.470 |
Why?
| | Premenopause | 9 | 2025 | 120 | 0.470 |
Why?
| | Cross-Sectional Studies | 23 | 2025 | 5743 | 0.460 |
Why?
| | Aniline Compounds | 3 | 2025 | 120 | 0.460 |
Why?
| | Risk Factors | 20 | 2025 | 10644 | 0.450 |
Why?
| | Heterocyclic Compounds, 4 or More Rings | 1 | 2014 | 19 | 0.440 |
Why?
| | Blood Glucose | 10 | 2017 | 2316 | 0.440 |
Why?
| | Hand Strength | 4 | 2025 | 136 | 0.440 |
Why?
| | Reflex | 6 | 2001 | 72 | 0.440 |
Why?
| | Collagen | 3 | 2021 | 457 | 0.430 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2025 | 135 | 0.430 |
Why?
| | Body Mass Index | 18 | 2015 | 2429 | 0.430 |
Why?
| | AMP-Activated Protein Kinases | 3 | 2017 | 195 | 0.430 |
Why?
| | Endothelium | 1 | 2014 | 119 | 0.420 |
Why?
| | Cognitive Dysfunction | 3 | 2025 | 441 | 0.420 |
Why?
| | Geriatric Assessment | 2 | 2015 | 225 | 0.420 |
Why?
| | Niacin | 1 | 2013 | 16 | 0.420 |
Why?
| | Nitrates | 4 | 2022 | 97 | 0.410 |
Why?
| | Proteome | 1 | 2018 | 494 | 0.410 |
Why?
| | Bufanolides | 1 | 2013 | 4 | 0.410 |
Why?
| | Atherosclerosis | 1 | 2018 | 406 | 0.410 |
Why?
| | Vitamin B Complex | 1 | 2013 | 40 | 0.410 |
Why?
| | Hindlimb | 1 | 2014 | 136 | 0.400 |
Why?
| | Locomotion | 1 | 2014 | 106 | 0.390 |
Why?
| | Eating | 2 | 2007 | 397 | 0.390 |
Why?
| | Aortic Diseases | 1 | 2014 | 120 | 0.390 |
Why?
| | Exercise Test | 12 | 2021 | 624 | 0.380 |
Why?
| | Risk Reduction Behavior | 1 | 2014 | 230 | 0.380 |
Why?
| | Arm | 7 | 2008 | 109 | 0.380 |
Why?
| | Nitric Oxide Donors | 1 | 2012 | 21 | 0.380 |
Why?
| | Ganglionic Blockers | 7 | 2008 | 9 | 0.380 |
Why?
| | Repetitive Sequences, Nucleic Acid | 2 | 2024 | 117 | 0.370 |
Why?
| | Carotid Artery Diseases | 2 | 2010 | 64 | 0.370 |
Why?
| | Obesity, Abdominal | 1 | 2012 | 46 | 0.370 |
Why?
| | Allopurinol | 2 | 2016 | 68 | 0.360 |
Why?
| | Pressoreceptors | 6 | 2001 | 19 | 0.360 |
Why?
| | Dose-Response Relationship, Drug | 8 | 2015 | 2056 | 0.360 |
Why?
| | I-kappa B Proteins | 2 | 2009 | 76 | 0.350 |
Why?
| | Arteritis | 1 | 2011 | 25 | 0.340 |
Why?
| | Adrenal Glands | 3 | 2000 | 79 | 0.340 |
Why?
| | Neurodegenerative Diseases | 2 | 2023 | 143 | 0.340 |
Why?
| | C-Reactive Protein | 3 | 2022 | 418 | 0.340 |
Why?
| | Oxidants | 1 | 2011 | 104 | 0.340 |
Why?
| | Ultrasonography | 11 | 2017 | 769 | 0.330 |
Why?
| | Postural Balance | 1 | 2014 | 247 | 0.330 |
Why?
| | Systole | 6 | 2020 | 175 | 0.330 |
Why?
| | Uric Acid | 1 | 2012 | 163 | 0.330 |
Why?
| | Behavior, Animal | 1 | 2014 | 516 | 0.330 |
Why?
| | Ventricular Function, Left | 4 | 2026 | 520 | 0.330 |
Why?
| | Colorado | 6 | 2024 | 4658 | 0.330 |
Why?
| | Cholesterol, LDL | 5 | 2008 | 363 | 0.330 |
Why?
| | Athletic Performance | 2 | 2012 | 85 | 0.320 |
Why?
| | Pilot Projects | 5 | 2025 | 1838 | 0.320 |
Why?
| | Analysis of Variance | 7 | 2011 | 1314 | 0.320 |
Why?
| | Forkhead Transcription Factors | 1 | 2011 | 203 | 0.310 |
Why?
| | Athletes | 2 | 2022 | 419 | 0.310 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2010 | 169 | 0.310 |
Why?
| | Antineoplastic Agents | 1 | 2021 | 2195 | 0.300 |
Why?
| | Peroxidase | 1 | 2010 | 174 | 0.300 |
Why?
| | Metabolome | 3 | 2018 | 374 | 0.300 |
Why?
| | Receptors, Adrenergic, beta-2 | 2 | 2007 | 34 | 0.300 |
Why?
| | Interleukins | 2 | 2022 | 252 | 0.300 |
Why?
| | Extremities | 2 | 2001 | 141 | 0.300 |
Why?
| | Blood Circulation | 4 | 2021 | 44 | 0.290 |
Why?
| | Biological Availability | 4 | 2021 | 137 | 0.290 |
Why?
| | Hot Temperature | 5 | 1993 | 408 | 0.290 |
Why?
| | Vitamin D Deficiency | 1 | 2010 | 188 | 0.290 |
Why?
| | Vitamin D | 2 | 2017 | 401 | 0.290 |
Why?
| | Interleukin-6 | 4 | 2024 | 781 | 0.280 |
Why?
| | Healthy Volunteers | 3 | 2018 | 213 | 0.280 |
Why?
| | Endothelin-1 | 2 | 2009 | 177 | 0.280 |
Why?
| | Cells, Cultured | 5 | 2025 | 4182 | 0.280 |
Why?
| | Administration, Oral | 5 | 2015 | 842 | 0.280 |
Why?
| | NG-Nitroarginine Methyl Ester | 4 | 2013 | 49 | 0.280 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2008 | 47 | 0.280 |
Why?
| | Cerebrovascular Circulation | 3 | 2025 | 272 | 0.280 |
Why?
| | Collagen Type I | 3 | 2014 | 140 | 0.280 |
Why?
| | Energy Intake | 6 | 2020 | 513 | 0.280 |
Why?
| | Peroneal Nerve | 5 | 2000 | 18 | 0.280 |
Why?
| | Leukocytes, Mononuclear | 1 | 2011 | 589 | 0.280 |
Why?
| | Upper Extremity | 1 | 2009 | 110 | 0.280 |
Why?
| | Kidney | 7 | 2025 | 1507 | 0.280 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 1906 | 0.280 |
Why?
| | Signal Transduction | 6 | 2014 | 5214 | 0.280 |
Why?
| | Posture | 6 | 2001 | 197 | 0.270 |
Why?
| | Oxygen | 11 | 2022 | 998 | 0.270 |
Why?
| | Sports | 5 | 2003 | 222 | 0.270 |
Why?
| | Hypercapnia | 2 | 2025 | 54 | 0.270 |
Why?
| | Phosphorylation | 6 | 2013 | 1781 | 0.270 |
Why?
| | Abdomen | 5 | 2004 | 140 | 0.270 |
Why?
| | Infusions, Intravenous | 5 | 2014 | 423 | 0.260 |
Why?
| | Adiposity | 1 | 2012 | 532 | 0.260 |
Why?
| | Regression Analysis | 10 | 2011 | 1013 | 0.260 |
Why?
| | Human Experimentation | 1 | 2007 | 13 | 0.260 |
Why?
| | Treatment Outcome | 7 | 2025 | 11365 | 0.260 |
Why?
| | Acetophenones | 3 | 2019 | 13 | 0.260 |
Why?
| | Trimethaphan | 5 | 2005 | 6 | 0.260 |
Why?
| | Enzyme Inhibitors | 4 | 2016 | 839 | 0.250 |
Why?
| | Swimming | 5 | 2002 | 49 | 0.250 |
Why?
| | Tunica Media | 3 | 2001 | 36 | 0.250 |
Why?
| | Phenylephrine | 5 | 2005 | 75 | 0.250 |
Why?
| | Electrocardiography | 9 | 2005 | 630 | 0.250 |
Why?
| | Congresses as Topic | 2 | 2018 | 226 | 0.250 |
Why?
| | Nitric Oxide Synthase | 3 | 2014 | 241 | 0.250 |
Why?
| | Gene Expression Regulation | 3 | 2017 | 2621 | 0.250 |
Why?
| | Proteins | 3 | 2009 | 1022 | 0.240 |
Why?
| | Pyridinium Compounds | 3 | 2025 | 30 | 0.240 |
Why?
| | Hypoxia | 6 | 1999 | 1177 | 0.240 |
Why?
| | Case-Control Studies | 5 | 2026 | 3625 | 0.240 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2008 | 550 | 0.240 |
Why?
| | Chemokine CXCL12 | 1 | 2026 | 89 | 0.240 |
Why?
| | Fatty Acids | 2 | 2019 | 452 | 0.240 |
Why?
| | Microcirculation | 2 | 2019 | 138 | 0.240 |
Why?
| | Sulfonamides | 3 | 2025 | 582 | 0.240 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2007 | 273 | 0.230 |
Why?
| | Trastuzumab | 1 | 2026 | 102 | 0.230 |
Why?
| | Thermogenesis | 1 | 2005 | 46 | 0.230 |
Why?
| | Carbon Dioxide | 3 | 2023 | 242 | 0.230 |
Why?
| | Recovery of Function | 4 | 2017 | 702 | 0.230 |
Why?
| | Brain | 6 | 2023 | 2892 | 0.230 |
Why?
| | Pyruvaldehyde | 1 | 2025 | 50 | 0.230 |
Why?
| | Aged, 80 and over | 14 | 2025 | 8072 | 0.230 |
Why?
| | Sodium Bicarbonate | 1 | 2025 | 46 | 0.230 |
Why?
| | Receptors, Adrenergic, alpha | 2 | 2002 | 20 | 0.230 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 2 | 2011 | 41 | 0.230 |
Why?
| | Cell Nucleus | 1 | 2008 | 612 | 0.230 |
Why?
| | Arginine | 1 | 2006 | 261 | 0.220 |
Why?
| | MicroRNAs | 1 | 2011 | 698 | 0.220 |
Why?
| | Carotid Artery, Internal | 1 | 2025 | 44 | 0.220 |
Why?
| | American Heart Association | 2 | 2020 | 302 | 0.220 |
Why?
| | Mitochondria, Muscle | 1 | 2026 | 121 | 0.220 |
Why?
| | Preventive Medicine | 2 | 2015 | 40 | 0.220 |
Why?
| | Acidosis | 1 | 2025 | 105 | 0.210 |
Why?
| | Veins | 5 | 2009 | 70 | 0.210 |
Why?
| | Apigenin | 1 | 2023 | 3 | 0.210 |
Why?
| | Respiratory Therapy | 1 | 2023 | 25 | 0.200 |
Why?
| | Skin | 4 | 2019 | 774 | 0.200 |
Why?
| | Lactates | 7 | 2007 | 85 | 0.200 |
Why?
| | Weight Loss | 2 | 2008 | 811 | 0.200 |
Why?
| | History, 21st Century | 1 | 2024 | 220 | 0.200 |
Why?
| | Xanthine Oxidase | 3 | 2009 | 81 | 0.200 |
Why?
| | Blueberry Plants | 1 | 2023 | 7 | 0.200 |
Why?
| | Tissue Culture Techniques | 2 | 2014 | 82 | 0.200 |
Why?
| | Hand | 8 | 1994 | 165 | 0.190 |
Why?
| | History, 20th Century | 1 | 2024 | 327 | 0.190 |
Why?
| | Blood Flow Velocity | 6 | 2019 | 415 | 0.190 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2014 | 198 | 0.190 |
Why?
| | Myocardium | 5 | 2010 | 928 | 0.190 |
Why?
| | Apoptosis | 1 | 2011 | 2519 | 0.190 |
Why?
| | Cholesterol | 5 | 1997 | 404 | 0.190 |
Why?
| | Anthropometry | 3 | 2011 | 208 | 0.190 |
Why?
| | Kidney Diseases | 2 | 2025 | 412 | 0.190 |
Why?
| | Acetylene | 2 | 2003 | 3 | 0.190 |
Why?
| | Authorship | 1 | 2023 | 46 | 0.190 |
Why?
| | Supine Position | 6 | 1999 | 38 | 0.190 |
Why?
| | Fibrinolysis | 2 | 2008 | 162 | 0.180 |
Why?
| | Sugars | 1 | 2022 | 42 | 0.180 |
Why?
| | Adrenal Medulla | 1 | 2002 | 9 | 0.180 |
Why?
| | Respiration | 7 | 1998 | 209 | 0.180 |
Why?
| | Cold Temperature | 7 | 2001 | 201 | 0.180 |
Why?
| | Coronary Disease | 6 | 1998 | 373 | 0.180 |
Why?
| | Citrulline | 1 | 2022 | 46 | 0.180 |
Why?
| | Terminology as Topic | 1 | 2023 | 250 | 0.180 |
Why?
| | Body Weight | 10 | 2019 | 1003 | 0.170 |
Why?
| | Universities | 1 | 2024 | 455 | 0.170 |
Why?
| | Cyclooxygenase 2 | 2 | 2014 | 175 | 0.170 |
Why?
| | Sirolimus | 3 | 2021 | 278 | 0.170 |
Why?
| | I-kappa B Kinase | 2 | 2011 | 54 | 0.170 |
Why?
| | Progesterone | 1 | 2002 | 258 | 0.170 |
Why?
| | Cancer Survivors | 1 | 2026 | 295 | 0.170 |
Why?
| | Nicotine | 1 | 2023 | 342 | 0.170 |
Why?
| | Fatty Liver | 1 | 2023 | 249 | 0.170 |
Why?
| | Weight Gain | 1 | 2004 | 550 | 0.170 |
Why?
| | Insulin | 11 | 2022 | 2497 | 0.170 |
Why?
| | Free Radical Scavengers | 2 | 2013 | 86 | 0.170 |
Why?
| | Manuscripts as Topic | 1 | 2000 | 2 | 0.160 |
Why?
| | Mexican Americans | 1 | 2001 | 114 | 0.160 |
Why?
| | DNA Transposable Elements | 1 | 2021 | 121 | 0.160 |
Why?
| | Extracellular Vesicles | 1 | 2022 | 162 | 0.160 |
Why?
| | Knee | 1 | 2000 | 69 | 0.160 |
Why?
| | DNA Methylation | 2 | 2024 | 667 | 0.160 |
Why?
| | Lipocalin-2 | 1 | 2020 | 80 | 0.160 |
Why?
| | Myocardial Reperfusion Injury | 2 | 2011 | 140 | 0.160 |
Why?
| | Lung | 4 | 1999 | 4101 | 0.160 |
Why?
| | Triglycerides | 4 | 2017 | 517 | 0.160 |
Why?
| | Fibrinogen | 2 | 1998 | 179 | 0.160 |
Why?
| | RNA, Untranslated | 1 | 2021 | 124 | 0.160 |
Why?
| | Functional Food | 1 | 2019 | 3 | 0.150 |
Why?
| | Pulmonary Circulation | 1 | 2001 | 425 | 0.150 |
Why?
| | Emotions | 1 | 2025 | 581 | 0.150 |
Why?
| | Menopause | 2 | 2006 | 317 | 0.150 |
Why?
| | Waist-Hip Ratio | 2 | 2012 | 37 | 0.150 |
Why?
| | Adrenergic alpha-Agonists | 3 | 2005 | 28 | 0.150 |
Why?
| | Adipose Tissue, White | 1 | 2019 | 42 | 0.150 |
Why?
| | Mentors | 1 | 2021 | 215 | 0.150 |
Why?
| | Fluorescent Antibody Technique | 3 | 2009 | 383 | 0.150 |
Why?
| | Adipokines | 1 | 2019 | 53 | 0.150 |
Why?
| | Rats | 11 | 2015 | 5610 | 0.150 |
Why?
| | Sex Factors | 4 | 2025 | 2092 | 0.150 |
Why?
| | Transforming Growth Factor beta | 2 | 2012 | 484 | 0.150 |
Why?
| | NF-KappaB Inhibitor alpha | 2 | 2009 | 50 | 0.150 |
Why?
| | Social Class | 1 | 2001 | 273 | 0.140 |
Why?
| | Lower Body Negative Pressure | 4 | 1992 | 26 | 0.140 |
Why?
| | Stroke Volume | 7 | 1998 | 607 | 0.140 |
Why?
| | Glomerular Filtration Rate | 2 | 2025 | 775 | 0.140 |
Why?
| | Linear Models | 2 | 2012 | 858 | 0.140 |
Why?
| | Guidelines as Topic | 1 | 2020 | 270 | 0.140 |
Why?
| | Metabolic Syndrome | 2 | 2019 | 354 | 0.140 |
Why?
| | Cohort Studies | 5 | 2013 | 5891 | 0.140 |
Why?
| | Leptin | 5 | 2019 | 239 | 0.130 |
Why?
| | Methionine | 1 | 2018 | 158 | 0.130 |
Why?
| | Cardiology | 1 | 2020 | 287 | 0.130 |
Why?
| | Adipocytes | 1 | 2019 | 222 | 0.130 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 1997 | 143 | 0.130 |
Why?
| | Unfolded Protein Response | 2 | 2017 | 59 | 0.130 |
Why?
| | Drug Monitoring | 1 | 2021 | 396 | 0.130 |
Why?
| | Calcitriol | 1 | 2017 | 58 | 0.130 |
Why?
| | Cholecalciferol | 1 | 2017 | 61 | 0.130 |
Why?
| | Neuromuscular Junction | 2 | 1995 | 65 | 0.130 |
Why?
| | Carotid Artery, Common | 1 | 2017 | 31 | 0.130 |
Why?
| | Stress, Psychological | 3 | 1995 | 1134 | 0.130 |
Why?
| | Heart Conduction System | 4 | 2002 | 92 | 0.120 |
Why?
| | Disease Models, Animal | 4 | 2025 | 4522 | 0.120 |
Why?
| | Hyperuricemia | 1 | 2016 | 45 | 0.120 |
Why?
| | Education, Graduate | 1 | 2016 | 33 | 0.120 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2026 | 1827 | 0.120 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2017 | 124 | 0.120 |
Why?
| | Students, Health Occupations | 1 | 2016 | 34 | 0.120 |
Why?
| | Insulin Resistance | 3 | 2018 | 1234 | 0.120 |
Why?
| | Age Distribution | 1 | 1997 | 398 | 0.120 |
Why?
| | Blood Coagulation | 1 | 1998 | 271 | 0.120 |
Why?
| | Methemoglobin | 1 | 2015 | 21 | 0.120 |
Why?
| | Gene Regulatory Networks | 1 | 2018 | 319 | 0.120 |
Why?
| | Walking | 3 | 2011 | 557 | 0.120 |
Why?
| | Risk Assessment | 2 | 2018 | 3577 | 0.120 |
Why?
| | Hemostasis | 2 | 1998 | 100 | 0.120 |
Why?
| | Myocardial Contraction | 3 | 1988 | 300 | 0.120 |
Why?
| | Program Development | 1 | 2018 | 371 | 0.120 |
Why?
| | Anaerobic Threshold | 3 | 2008 | 28 | 0.110 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 1995 | 53 | 0.110 |
Why?
| | Middle Cerebral Artery | 2 | 2025 | 55 | 0.110 |
Why?
| | NADPH Oxidase 4 | 1 | 2014 | 8 | 0.110 |
Why?
| | Urinalysis | 1 | 2015 | 80 | 0.110 |
Why?
| | Lipid Metabolism | 1 | 2018 | 524 | 0.110 |
Why?
| | Src Homology 2 Domain-Containing, Transforming Protein 1 | 1 | 2014 | 11 | 0.110 |
Why?
| | Shc Signaling Adaptor Proteins | 1 | 2014 | 11 | 0.110 |
Why?
| | Skinfold Thickness | 4 | 1999 | 46 | 0.110 |
Why?
| | Rotenone | 1 | 2014 | 16 | 0.110 |
Why?
| | Rejuvenation | 1 | 2014 | 19 | 0.110 |
Why?
| | Mitochondrial Proteins | 1 | 2016 | 262 | 0.110 |
Why?
| | Mobility Limitation | 1 | 2014 | 63 | 0.100 |
Why?
| | Neurons | 2 | 1995 | 1636 | 0.100 |
Why?
| | Nutritional Status | 1 | 2016 | 360 | 0.100 |
Why?
| | Plasma Volume | 3 | 2002 | 20 | 0.100 |
Why?
| | Liver | 3 | 2017 | 1864 | 0.100 |
Why?
| | Cardiotonic Agents | 1 | 2014 | 95 | 0.100 |
Why?
| | Administration, Cutaneous | 1 | 2013 | 129 | 0.100 |
Why?
| | Plethysmography | 4 | 2007 | 108 | 0.100 |
Why?
| | Program Evaluation | 1 | 2018 | 937 | 0.100 |
Why?
| | Breast Neoplasms | 1 | 2026 | 2318 | 0.100 |
Why?
| | Multivariate Analysis | 2 | 2012 | 1510 | 0.100 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 1994 | 120 | 0.100 |
Why?
| | Epidemiology | 1 | 2013 | 33 | 0.100 |
Why?
| | Cell Cycle | 1 | 2016 | 648 | 0.100 |
Why?
| | Diabetic Angiopathies | 1 | 2015 | 252 | 0.100 |
Why?
| | Statistics as Topic | 2 | 2011 | 298 | 0.100 |
Why?
| | Absorptiometry, Photon | 2 | 2012 | 272 | 0.100 |
Why?
| | Respiratory Mechanics | 1 | 1993 | 73 | 0.100 |
Why?
| | Administration, Sublingual | 1 | 2012 | 12 | 0.100 |
Why?
| | Body Temperature | 5 | 1991 | 224 | 0.090 |
Why?
| | Pyrogallol | 1 | 2012 | 3 | 0.090 |
Why?
| | Hypotension | 1 | 1993 | 126 | 0.090 |
Why?
| | Catecholamines | 5 | 1996 | 89 | 0.090 |
Why?
| | Mental Processes | 1 | 1992 | 35 | 0.090 |
Why?
| | Aminoimidazole Carboxamide | 1 | 2012 | 12 | 0.090 |
Why?
| | Ribonucleotides | 1 | 2012 | 26 | 0.090 |
Why?
| | Pulmonary Gas Exchange | 4 | 2007 | 117 | 0.090 |
Why?
| | Prospective Studies | 6 | 2021 | 7899 | 0.090 |
Why?
| | Waist Circumference | 1 | 2012 | 137 | 0.090 |
Why?
| | Naphthols | 1 | 2011 | 6 | 0.090 |
Why?
| | Hysterectomy | 1 | 2012 | 139 | 0.090 |
Why?
| | Receptors, Adrenergic, beta-3 | 1 | 2011 | 4 | 0.090 |
Why?
| | Nitroso Compounds | 1 | 2011 | 7 | 0.090 |
Why?
| | Myography | 1 | 2011 | 10 | 0.090 |
Why?
| | Metabolism | 2 | 2001 | 43 | 0.090 |
Why?
| | Chemokine CCL2 | 1 | 2011 | 115 | 0.090 |
Why?
| | Least-Squares Analysis | 1 | 2011 | 78 | 0.090 |
Why?
| | Forkhead Box Protein O3 | 1 | 2011 | 17 | 0.090 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2010 | 17 | 0.080 |
Why?
| | Diastole | 3 | 2003 | 141 | 0.080 |
Why?
| | Glucose Tolerance Test | 3 | 2018 | 368 | 0.080 |
Why?
| | Connective Tissue | 1 | 2010 | 38 | 0.080 |
Why?
| | Endorphins | 1 | 1990 | 10 | 0.080 |
Why?
| | Mice, Inbred Strains | 1 | 2011 | 408 | 0.080 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2010 | 58 | 0.080 |
Why?
| | Retrospective Studies | 4 | 2022 | 16741 | 0.080 |
Why?
| | Receptors, Calcitriol | 1 | 2010 | 55 | 0.080 |
Why?
| | Caspases | 1 | 2011 | 246 | 0.080 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 1091 | 0.080 |
Why?
| | Decompression | 1 | 1990 | 3 | 0.080 |
Why?
| | United States | 3 | 2020 | 15553 | 0.080 |
Why?
| | Phosphoproteins | 1 | 2012 | 337 | 0.080 |
Why?
| | Benzamides | 1 | 2011 | 223 | 0.080 |
Why?
| | Lipoproteins, HDL | 3 | 1984 | 78 | 0.080 |
Why?
| | Communication | 1 | 2016 | 953 | 0.080 |
Why?
| | Fibronectins | 1 | 2010 | 136 | 0.080 |
Why?
| | Prediabetic State | 1 | 2013 | 253 | 0.080 |
Why?
| | Phenotype | 2 | 2024 | 3211 | 0.080 |
Why?
| | Follow-Up Studies | 2 | 2018 | 5308 | 0.080 |
Why?
| | Diet Records | 1 | 2009 | 84 | 0.080 |
Why?
| | Curriculum | 1 | 2016 | 1047 | 0.080 |
Why?
| | Subclavian Artery | 1 | 1989 | 28 | 0.080 |
Why?
| | Cyclooxygenase 1 | 1 | 2009 | 26 | 0.070 |
Why?
| | Receptor, Endothelin A | 1 | 2009 | 63 | 0.070 |
Why?
| | Leukocyte Count | 1 | 2010 | 317 | 0.070 |
Why?
| | Acclimatization | 1 | 1990 | 172 | 0.070 |
Why?
| | Prognosis | 1 | 2018 | 4152 | 0.070 |
Why?
| | Carotid Sinus | 1 | 1988 | 2 | 0.070 |
Why?
| | Probability | 1 | 2010 | 308 | 0.070 |
Why?
| | Blood Pressure Determination | 1 | 2010 | 144 | 0.070 |
Why?
| | Arrhythmia, Sinus | 1 | 1988 | 3 | 0.070 |
Why?
| | Sulfaphenazole | 1 | 2008 | 3 | 0.070 |
Why?
| | Cytochrome P-450 CYP2C9 | 1 | 2008 | 19 | 0.070 |
Why?
| | omega-N-Methylarginine | 1 | 2008 | 29 | 0.070 |
Why?
| | Rats, Sprague-Dawley | 2 | 2010 | 2531 | 0.070 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2010 | 261 | 0.070 |
Why?
| | Homeostasis | 3 | 2021 | 641 | 0.070 |
Why?
| | Tetralogy of Fallot | 1 | 1989 | 73 | 0.070 |
Why?
| | Aortic Coarctation | 1 | 1989 | 80 | 0.070 |
Why?
| | Propranolol | 4 | 2001 | 46 | 0.070 |
Why?
| | Biomechanical Phenomena | 1 | 2012 | 867 | 0.070 |
Why?
| | Diet, High-Fat | 2 | 2021 | 260 | 0.070 |
Why?
| | Leukocytes | 1 | 2010 | 299 | 0.070 |
Why?
| | Calorimetry, Indirect | 2 | 2005 | 86 | 0.070 |
Why?
| | Estrogen Receptor alpha | 1 | 2009 | 147 | 0.070 |
Why?
| | Microscopy, Fluorescence | 1 | 2009 | 420 | 0.070 |
Why?
| | Interferon-gamma | 1 | 2011 | 791 | 0.070 |
Why?
| | Vasoconstrictor Agents | 2 | 2007 | 138 | 0.070 |
Why?
| | Hyperemia | 1 | 1988 | 49 | 0.070 |
Why?
| | Hyperoxia | 2 | 1999 | 99 | 0.060 |
Why?
| | Catalase | 1 | 2007 | 134 | 0.060 |
Why?
| | Electrophysiology | 3 | 1993 | 220 | 0.060 |
Why?
| | Databases, Factual | 1 | 2013 | 1465 | 0.060 |
Why?
| | Kinetics | 3 | 1997 | 1628 | 0.060 |
Why?
| | Telomere | 1 | 2010 | 282 | 0.060 |
Why?
| | Amidohydrolases | 1 | 2006 | 32 | 0.060 |
Why?
| | Gene Expression | 1 | 2011 | 1505 | 0.060 |
Why?
| | Hormones | 2 | 2002 | 138 | 0.060 |
Why?
| | Data Interpretation, Statistical | 1 | 2008 | 377 | 0.060 |
Why?
| | Severity of Illness Index | 2 | 2016 | 2936 | 0.060 |
Why?
| | Adrenergic beta-Antagonists | 3 | 2001 | 228 | 0.060 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2007 | 142 | 0.060 |
Why?
| | Body Fat Distribution | 1 | 2005 | 47 | 0.060 |
Why?
| | Hematocrit | 2 | 1997 | 104 | 0.060 |
Why?
| | Heart Ventricles | 3 | 2003 | 755 | 0.060 |
Why?
| | Codon | 1 | 2005 | 92 | 0.060 |
Why?
| | Arterioles | 1 | 2025 | 57 | 0.060 |
Why?
| | Ultrasonography, Doppler, Transcranial | 1 | 2025 | 45 | 0.060 |
Why?
| | Dihydroxyphenylalanine | 2 | 1995 | 9 | 0.060 |
Why?
| | Methoxyhydroxyphenylglycol | 2 | 1995 | 11 | 0.060 |
Why?
| | Fibroblasts | 1 | 2010 | 1044 | 0.060 |
Why?
| | Erythrocyte Volume | 2 | 1994 | 6 | 0.050 |
Why?
| | Vital Capacity | 2 | 2000 | 311 | 0.050 |
Why?
| | Vasopressins | 1 | 2005 | 60 | 0.050 |
Why?
| | Thigh | 2 | 2003 | 49 | 0.050 |
Why?
| | Calorimetry | 1 | 2004 | 71 | 0.050 |
Why?
| | Loneliness | 1 | 2025 | 54 | 0.050 |
Why?
| | Imidazoles | 1 | 2025 | 252 | 0.050 |
Why?
| | Recombinant Proteins | 2 | 2018 | 1369 | 0.050 |
Why?
| | Osmolar Concentration | 3 | 2001 | 166 | 0.050 |
Why?
| | Up-Regulation | 1 | 2007 | 863 | 0.050 |
Why?
| | Postprandial Period | 1 | 2004 | 116 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2011 | 2542 | 0.050 |
Why?
| | Stem Cells | 1 | 2008 | 619 | 0.050 |
Why?
| | Elastic Modulus | 1 | 2024 | 124 | 0.050 |
Why?
| | Stroke | 2 | 2011 | 1213 | 0.050 |
Why?
| | Mice, Transgenic | 2 | 2019 | 2194 | 0.050 |
Why?
| | Macrophages | 1 | 2011 | 1506 | 0.050 |
Why?
| | Powders | 1 | 2023 | 44 | 0.050 |
Why?
| | RNA, Messenger | 1 | 2011 | 2852 | 0.050 |
Why?
| | Butanols | 1 | 2022 | 6 | 0.050 |
Why?
| | Hexanols | 1 | 2022 | 7 | 0.050 |
Why?
| | Biology | 1 | 2023 | 92 | 0.050 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2023 | 138 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2011 | 2026 | 0.050 |
Why?
| | Femur | 2 | 2001 | 271 | 0.050 |
Why?
| | Evans Blue | 1 | 2002 | 8 | 0.050 |
Why?
| | Rats, Inbred Strains | 3 | 1991 | 332 | 0.050 |
Why?
| | Phenols | 1 | 2023 | 113 | 0.050 |
Why?
| | Ganglia, Autonomic | 1 | 2001 | 5 | 0.050 |
Why?
| | Electromyography | 3 | 1989 | 413 | 0.050 |
Why?
| | Phentolamine | 1 | 2001 | 20 | 0.050 |
Why?
| | Mesentery | 1 | 2002 | 45 | 0.050 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2001 | 34 | 0.040 |
Why?
| | Ischemia | 5 | 1994 | 416 | 0.040 |
Why?
| | Infusions, Intra-Arterial | 1 | 2001 | 62 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2012 | 2779 | 0.040 |
Why?
| | Respiratory Function Tests | 2 | 1994 | 560 | 0.040 |
Why?
| | Men | 1 | 2001 | 22 | 0.040 |
Why?
| | Lactic Acid | 4 | 1995 | 308 | 0.040 |
Why?
| | Genotype | 1 | 2007 | 1877 | 0.040 |
Why?
| | Acarbose | 1 | 2021 | 2 | 0.040 |
Why?
| | Drugs, Chinese Herbal | 1 | 2021 | 22 | 0.040 |
Why?
| | Blood Viscosity | 1 | 2001 | 18 | 0.040 |
Why?
| | Tidal Volume | 2 | 1993 | 110 | 0.040 |
Why?
| | Neurons, Afferent | 2 | 1993 | 101 | 0.040 |
Why?
| | Models, Biological | 2 | 2004 | 1831 | 0.040 |
Why?
| | Thoracic Arteries | 1 | 2000 | 4 | 0.040 |
Why?
| | Clinical Trials as Topic | 2 | 2014 | 1043 | 0.040 |
Why?
| | Catheterization | 1 | 2001 | 185 | 0.040 |
Why?
| | Pressure | 1 | 2001 | 232 | 0.040 |
Why?
| | Mouth | 1 | 2021 | 88 | 0.040 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2020 | 42 | 0.040 |
Why?
| | Hypertrophy | 1 | 2001 | 134 | 0.040 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2015 | 2575 | 0.040 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2003 | 377 | 0.040 |
Why?
| | Thinness | 1 | 2000 | 98 | 0.040 |
Why?
| | Organ Size | 2 | 2016 | 481 | 0.040 |
Why?
| | Mexico | 1 | 2001 | 230 | 0.040 |
Why?
| | Corticotropin-Releasing Hormone | 2 | 1991 | 72 | 0.040 |
Why?
| | Rats, Inbred F344 | 2 | 1990 | 265 | 0.040 |
Why?
| | Stress, Mechanical | 2 | 2001 | 496 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2005 | 2086 | 0.040 |
Why?
| | NADP | 1 | 2019 | 51 | 0.040 |
Why?
| | Head-Down Tilt | 1 | 1999 | 6 | 0.040 |
Why?
| | Myocardial Infarction | 2 | 2005 | 1072 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2024 | 686 | 0.040 |
Why?
| | Receptors, Interleukin-1 Type I | 1 | 2018 | 25 | 0.040 |
Why?
| | Hyperinsulinism | 1 | 2019 | 115 | 0.040 |
Why?
| | Antihypertensive Agents | 1 | 2022 | 515 | 0.040 |
Why?
| | Oncogene Protein p21(ras) | 1 | 2017 | 15 | 0.030 |
Why?
| | Prevalence | 2 | 2005 | 2830 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2024 | 861 | 0.030 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 1998 | 89 | 0.030 |
Why?
| | Biological Transport | 1 | 2019 | 412 | 0.030 |
Why?
| | Acute Disease | 1 | 2000 | 1015 | 0.030 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 1998 | 92 | 0.030 |
Why?
| | Mathematics | 2 | 1996 | 103 | 0.030 |
Why?
| | Automation | 1 | 1997 | 102 | 0.030 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 1998 | 153 | 0.030 |
Why?
| | Rotarod Performance Test | 1 | 2017 | 16 | 0.030 |
Why?
| | Echocardiography | 2 | 2005 | 652 | 0.030 |
Why?
| | Splanchnic Circulation | 2 | 1999 | 13 | 0.030 |
Why?
| | Cell Respiration | 1 | 2017 | 107 | 0.030 |
Why?
| | Adenylate Kinase | 1 | 2016 | 27 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2001 | 1324 | 0.030 |
Why?
| | Weight Lifting | 3 | 1988 | 32 | 0.030 |
Why?
| | Muscle Development | 1 | 1997 | 115 | 0.030 |
Why?
| | Myoblasts | 1 | 2017 | 82 | 0.030 |
Why?
| | Receptors, Interleukin-1 | 1 | 2017 | 215 | 0.030 |
Why?
| | Body Height | 1 | 1997 | 208 | 0.030 |
Why?
| | Tissue Plasminogen Activator | 1 | 1998 | 239 | 0.030 |
Why?
| | Pain | 2 | 1992 | 781 | 0.030 |
Why?
| | Oxidative Phosphorylation | 1 | 2017 | 209 | 0.030 |
Why?
| | Cholesterol, HDL | 3 | 1984 | 197 | 0.030 |
Why?
| | Depression | 1 | 2025 | 1512 | 0.030 |
Why?
| | Indicator Dilution Techniques | 1 | 1995 | 12 | 0.030 |
Why?
| | Haplorhini | 1 | 2015 | 51 | 0.030 |
Why?
| | Menstruation | 1 | 1995 | 43 | 0.030 |
Why?
| | Receptors, Leptin | 1 | 2015 | 25 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2019 | 3006 | 0.030 |
Why?
| | Protein Kinases | 1 | 2017 | 310 | 0.030 |
Why?
| | Resilience, Psychological | 1 | 2017 | 137 | 0.030 |
Why?
| | Autonomic Fibers, Postganglionic | 1 | 1994 | 1 | 0.030 |
Why?
| | Spectrophotometry | 1 | 1994 | 60 | 0.030 |
Why?
| | Median Nerve | 1 | 1994 | 27 | 0.030 |
Why?
| | Neurotransmitter Agents | 1 | 1995 | 81 | 0.030 |
Why?
| | Homozygote | 1 | 2015 | 201 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2015 | 309 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2014 | 62 | 0.030 |
Why?
| | Gated Blood-Pool Imaging | 1 | 1994 | 4 | 0.030 |
Why?
| | Health | 1 | 2014 | 83 | 0.030 |
Why?
| | Heterozygote | 1 | 2015 | 311 | 0.030 |
Why?
| | Point Mutation | 1 | 2015 | 243 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2003 | 3380 | 0.030 |
Why?
| | Activating Transcription Factor 6 | 1 | 2013 | 20 | 0.030 |
Why?
| | eIF-2 Kinase | 1 | 2013 | 31 | 0.030 |
Why?
| | Educational Measurement | 1 | 2016 | 324 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2017 | 539 | 0.020 |
Why?
| | Disability Evaluation | 1 | 2015 | 304 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2017 | 861 | 0.020 |
Why?
| | Reflex, Stretch | 1 | 1993 | 10 | 0.020 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2016 | 441 | 0.020 |
Why?
| | Denervation | 1 | 1993 | 25 | 0.020 |
Why?
| | Heart-Lung Transplantation | 1 | 1993 | 13 | 0.020 |
Why?
| | Venous Pressure | 1 | 1992 | 5 | 0.020 |
Why?
| | Chemoreceptor Cells | 1 | 1993 | 53 | 0.020 |
Why?
| | Endoribonucleases | 1 | 2013 | 79 | 0.020 |
Why?
| | Microbiota | 1 | 2021 | 759 | 0.020 |
Why?
| | Age of Onset | 1 | 2014 | 548 | 0.020 |
Why?
| | Synaptic Transmission | 1 | 1995 | 295 | 0.020 |
Why?
| | Tissue Distribution | 1 | 1993 | 330 | 0.020 |
Why?
| | Fingers | 1 | 2013 | 106 | 0.020 |
Why?
| | Skin Temperature | 1 | 1992 | 31 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2016 | 651 | 0.020 |
Why?
| | Ovariectomy | 1 | 2012 | 160 | 0.020 |
Why?
| | Cardiography, Impedance | 1 | 1991 | 9 | 0.020 |
Why?
| | Cell Line | 1 | 2017 | 2897 | 0.020 |
Why?
| | Task Performance and Analysis | 1 | 1992 | 196 | 0.020 |
Why?
| | Endoplasmic Reticulum | 1 | 2013 | 263 | 0.020 |
Why?
| | Renal Circulation | 1 | 1991 | 76 | 0.020 |
Why?
| | Inspiratory Capacity | 1 | 1990 | 3 | 0.020 |
Why?
| | Metformin | 1 | 2014 | 331 | 0.020 |
Why?
| | Acupuncture Therapy | 1 | 1990 | 23 | 0.020 |
Why?
| | Arousal | 1 | 1991 | 158 | 0.020 |
Why?
| | Blood Pressure Monitors | 1 | 1989 | 2 | 0.020 |
Why?
| | Precision Medicine | 1 | 2014 | 444 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2011 | 790 | 0.020 |
Why?
| | Anorexia Nervosa | 1 | 1990 | 78 | 0.020 |
Why?
| | Lipoproteins | 2 | 1988 | 163 | 0.020 |
Why?
| | Total Lung Capacity | 1 | 1988 | 32 | 0.020 |
Why?
| | Fever | 1 | 1990 | 310 | 0.020 |
Why?
| | Menstrual Cycle | 1 | 2009 | 139 | 0.020 |
Why?
| | Saponins | 1 | 1988 | 9 | 0.020 |
Why?
| | Neural Inhibition | 1 | 1989 | 176 | 0.020 |
Why?
| | Postoperative Period | 1 | 1989 | 361 | 0.020 |
Why?
| | Digoxin | 1 | 1988 | 26 | 0.020 |
Why?
| | Ultrasonography, Doppler, Duplex | 1 | 2007 | 40 | 0.020 |
Why?
| | Adrenergic Fibers | 1 | 1987 | 5 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2009 | 1064 | 0.020 |
Why?
| | Depressive Disorder | 1 | 1990 | 376 | 0.020 |
Why?
| | Child | 3 | 1997 | 22725 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2007 | 203 | 0.020 |
Why?
| | Forced Expiratory Volume | 1 | 1988 | 485 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2013 | 1171 | 0.020 |
Why?
| | Down-Regulation | 1 | 2009 | 644 | 0.020 |
Why?
| | Pain Management | 1 | 1990 | 406 | 0.020 |
Why?
| | Fatigue | 1 | 1988 | 349 | 0.020 |
Why?
| | Heart Block | 1 | 1986 | 40 | 0.020 |
Why?
| | Environmental Exposure | 1 | 1991 | 588 | 0.010 |
Why?
| | Peptide Fragments | 1 | 1990 | 698 | 0.010 |
Why?
| | Syncope | 1 | 1986 | 58 | 0.010 |
Why?
| | Blood Proteins | 1 | 1988 | 247 | 0.010 |
Why?
| | Feedback | 1 | 2005 | 180 | 0.010 |
Why?
| | Anabolic Agents | 1 | 1984 | 13 | 0.010 |
Why?
| | Hemostatics | 1 | 2005 | 61 | 0.010 |
Why?
| | Dogs | 1 | 2005 | 427 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2011 | 1671 | 0.010 |
Why?
| | Affect | 1 | 2007 | 315 | 0.010 |
Why?
| | Drug Tolerance | 1 | 1984 | 105 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2011 | 3109 | 0.010 |
Why?
| | C-Peptide | 1 | 1984 | 171 | 0.010 |
Why?
| | Arrhythmias, Cardiac | 1 | 1986 | 348 | 0.010 |
Why?
| | Methods | 1 | 1983 | 68 | 0.010 |
Why?
| | Work Capacity Evaluation | 1 | 2002 | 11 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1983 | 172 | 0.010 |
Why?
| | Androgens | 1 | 1984 | 194 | 0.010 |
Why?
| | Wrestling | 1 | 1982 | 3 | 0.010 |
Why?
| | Gymnastics | 1 | 1982 | 22 | 0.010 |
Why?
| | Motivation | 1 | 2007 | 609 | 0.010 |
Why?
| | Heart Arrest | 1 | 1986 | 399 | 0.010 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2001 | 54 | 0.010 |
Why?
| | Sodium Chloride | 1 | 2001 | 141 | 0.010 |
Why?
| | Efferent Pathways | 2 | 1992 | 19 | 0.010 |
Why?
| | Renal Veins | 1 | 1999 | 18 | 0.010 |
Why?
| | Jugular Veins | 1 | 1999 | 42 | 0.010 |
Why?
| | Models, Cardiovascular | 1 | 2000 | 198 | 0.010 |
Why?
| | Metabolic Clearance Rate | 1 | 1998 | 117 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 2001 | 505 | 0.010 |
Why?
| | Oscillometry | 1 | 1998 | 36 | 0.010 |
Why?
| | Self Concept | 1 | 1996 | 257 | 0.010 |
Why?
| | Injections, Intraventricular | 1 | 1990 | 55 | 0.010 |
Why?
| | Pain Measurement | 1 | 1992 | 558 | 0.000 |
Why?
| | Pancreatic Hormones | 1 | 1988 | 3 | 0.000 |
Why?
| | Cardenolides | 1 | 1988 | 1 | 0.000 |
Why?
| | Glycerol | 1 | 1988 | 90 | 0.000 |
Why?
| | Growth Hormone | 1 | 1988 | 99 | 0.000 |
Why?
| | Thyroid Hormones | 1 | 1988 | 68 | 0.000 |
Why?
| | Fatty Acids, Nonesterified | 1 | 1988 | 158 | 0.000 |
Why?
| | Insulin-Like Growth Factor I | 1 | 1988 | 318 | 0.000 |
Why?
| | Differential Threshold | 1 | 1985 | 5 | 0.000 |
Why?
| | Maximal Voluntary Ventilation | 1 | 1985 | 9 | 0.000 |
Why?
| | Risk | 1 | 1987 | 906 | 0.000 |
Why?
| | Bicycling | 1 | 1985 | 122 | 0.000 |
Why?
| | Ammonia | 1 | 1984 | 64 | 0.000 |
Why?
| | Action Potentials | 1 | 1987 | 513 | 0.000 |
Why?
| | Testosterone | 1 | 1984 | 423 | 0.000 |
Why?
| | Substance-Related Disorders | 1 | 1984 | 1113 | 0.000 |
Why?
|
|
Seals's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|